ArticleJournal of robotic surgery2026
Dehydrated human amniotic membrane for early return of erectile function after robotic radical prostatectomy: a 10-year journey and lessons learned.
Article in Journal of robotic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The first description of dehydrated human amniotic membrane (dHAM) use in robotic urologic surgery was by Razdan et al. in 2014 at the World Congress of Endourology. Since then, it has been utilized as a nerve and anastomotic wrap to enhance early return of erectile function and continence, respectively, during robotic radical prostatectomy (RALP). We describe our ten-year experience with dHAM as a nerve wrap. After obtaining hospital institutional review board (IRB) approval, a retrospective review of a prospectively maintained single center prostate cancer database was performed. All men undergoing RALP with dHAM by a single high-volume surgeon were examined and compared to a cohort of men who underwent RALP alone. Groups were matched demographically, clinically, and biochemically. Potency was defined as the ability to have satisfactory penetrative intercourse > 50% of time and a SHIM score of ≥ 17. A total of 2,560 men underwent bilateral nerve sparing (ns)RALP with dHAM from 2014 to 2024 (Group 1). These were matched to 1,495 men who underwent nsRALP without dHAM (Group 2). Baseline patient and tumor characteristics are found in Table 1. Mean follow up was 8 years. The mean number of days until first erection was 7 vs. 14 (p < 0.05) in Groups 1 and 2. The mean number of days until erection sufficient for penetration was 21 vs. 36 (p < 0.05). The percent of potent patients in Group 1 at 3, 6, 12, and 24 months was 75%, 87%, 98%, 98%. The percent of potent patients in Group 2 during the same time frame was 60%, 78%, 90%, 94% (p < 0.05). There was no difference in complications or oncological outcomes between the two groups. A subgroup analysis stratifying patients based on age showed lower erectile function recovery in men over the age of 60 in Group 2. dHAM is a safe adjunct at the time of RALP to hasten return of erectile function as well as improve 12-month and 24-month potency rates without compromising oncological outcomes. Men over the age of 60, especially, show improved 12- and 24-month potency with dHAM.
Indexed as
Identifiers
42873363What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.